Fred Hutchinson Cancer Research Center, Tokai University School of Medicine
Verified email at - Homepage
Cited by
Cited by
Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway
I Garcia-Higuera, T Taniguchi, S Ganesan, MS Meyn, C Timmers, J Hejna, ...
Molecular cell 7 (2), 249-262, 2001
Biallelic inactivation of BRCA2 in Fanconi anemia
NG Howlett, T Taniguchi, S Olson, B Cox, Q Waisfisz, C de Die-Smulders, ...
Science 297 (5581), 606-609, 2002
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
W Sakai, EM Swisher, BY Karlan, MK Agarwal, J Higgins, C Friedman, ...
Nature 451 (7182), 1116-1120, 2008
Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors
T Taniguchi, M Tischkowitz, N Ameziane, SV Hodgson, CG Mathew, ...
Nature medicine 9 (5), 568-574, 2003
Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways
T Taniguchi, I Garcia-Higuera, B Xu, PR Andreassen, RC Gregory, ST Kim, ...
Cell 109 (4), 459-472, 2002
S-phase–specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51
T Taniguchi, I Garcia-Higuera, PR Andreassen, RC Gregory, M Grompe, ...
Blood 100 (7), 2414-2420, 2002
Positional cloning of a novel Fanconi anemia gene, FANCD2
C Timmers, T Taniguchi, J Hejna, C Reifsteck, L Lucas, D Bruun, ...
Molecular cell 7 (2), 241-248, 2001
ATR couples FANCD2 monoubiquitination to the DNA-damage response
PR Andreassen, AD D'Andrea, T Taniguchi
Genes & development 18 (16), 1958-1963, 2004
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance
EM Swisher, W Sakai, BY Karlan, K Wurz, N Urban, T Taniguchi
Cancer research 68 (8), 2581-2586, 2008
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas
B Norquist, KA Wurz, CC Pennil, R Garcia, J Gross, W Sakai, BY Karlan, ...
Journal of clinical oncology 29 (22), 3008, 2011
Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer
PA Konstantinopoulos, D Spentzos, BY Karlan, T Taniguchi, E Fountzilas, ...
Journal of clinical oncology 28 (22), 3555, 2010
Molecular pathogenesis of Fanconi anemia: recent progress
T Taniguchi, AD D'Andrea
Blood 107 (11), 4223-4233, 2006
Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair
K Nakanishi, YG Yang, AJ Pierce, T Taniguchi, M Digweed, AD D'Andrea, ...
Proceedings of the National Academy of Sciences 102 (4), 1110-1115, 2005
Interaction of FANCD2 and NBS1 in the DNA damage response
K Nakanishi, T Taniguchi, V Ranganathan, HV New, LA Moreau, ...
Nature cell biology 4 (12), 913-920, 2002
Cancer survivorship—genetic susceptibility and second primary cancers: research strategies and recommendations
LB Travis, CS Rabkin, LM Brown, JM Allan, BP Alter, CB Ambrosone, ...
Journal of the National Cancer Institute 98 (1), 15-25, 2006
The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability
NG Howlett, T Taniguchi, SG Durkin, AD D'Andrea, TW Glover
Human molecular genetics 14 (5), 693-701, 2005
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma
W Sakai, EM Swisher, C Jacquemont, KV Chandramohan, FJ Couch, ...
Cancer research 69 (16), 6381-6386, 2009
Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway
D Chirnomas, T Taniguchi, M de la Vega, AP Vaidya, M Vasserman, ...
Molecular cancer therapeutics 5 (4), 952-961, 2006
Proteasome function is required for DNA damage response and fanconi anemia pathway activation
C Jacquemont, T Taniguchi
Cancer research 67 (15), 7395-7405, 2007
Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance
GPH Ho, S Margossian, T Taniguchi, AD D'Andrea
Molecular and cellular biology 26 (18), 7005-7015, 2006
The system can't perform the operation now. Try again later.
Articles 1–20